Detalhe da pesquisa
1.
Extreme thrombocytosis with an aggressive evolution harboring a novel variant of calreticulin (CALR) in exon 3.
Eur J Haematol
; 112(3): 475-478, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37918825
2.
DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.
Br J Cancer
; 118(8): 1062-1073, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29500406
3.
Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.
Blood
; 117(4): 1280-90, 2011 Jan 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-21097672
4.
Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma.
Front Oncol
; 13: 1271847, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38125947
5.
Comprehensive characterization of the epigenetic landscape in Multiple Myeloma.
Theranostics
; 12(4): 1715-1729, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35198065
6.
The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance.
Front Immunol
; 13: 983181, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36569948
7.
Mobilization of plasma cells in healthy individuals treated with granulocyte colony-stimulating factor for haematopoietic stem cell collection.
Immunology
; 132(2): 266-72, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21039470
8.
Gene expression profiling and real-time PCR analyses identify novel potential cancer-testis antigens in multiple myeloma.
J Immunol
; 183(2): 832-40, 2009 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19542363
9.
G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor-mediated cell death.
Blood Adv
; 5(9): 2325-2338, 2021 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33938943
10.
RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma.
J Pers Med
; 11(10)2021 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34683129
11.
Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance.
Theranostics
; 9(2): 540-553, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30809292
12.
BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma.
Cytometry B Clin Cytom
; 96(3): 209-214, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30417559
13.
Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry.
Cytometry B Clin Cytom
; 94(3): 484-492, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28865180
14.
PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs.
Clin Epigenetics
; 10(1): 121, 2018 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30285865
15.
EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma.
Leukemia
; 37(9): 1925-1928, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37532787
16.
CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma.
Oncotarget
; 8(58): 98931-98944, 2017 Nov 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-29228738
17.
Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays.
Oncogene
; 21(44): 6848-57, 2002 Oct 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-12360412
18.
Comparison of murine leukemia virus, human immunodeficiency virus, and adeno-associated virus vectors for gene transfer in multiple myeloma: lentiviral vectors demonstrate a striking capacity to transduce low-proliferating primary tumor cells.
Hum Gene Ther
; 14(18): 1727-39, 2003 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-14670124
19.
Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors.
Mol Cancer Ther
; 11(12): 2685-92, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23087257
20.
Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?
Oncotarget
; 3(11): 1335-47, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23154454